Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Shah on the Significance of PARP Inhibitors in Ovarian Cancer

November 30th 2021

Payal D. Shah, MD, discusses the significance of the emergence of PARP inhibitors in ovarian cancer.

Niraparib Demonstrates PFS Benefit in Chinese Population With Advanced Ovarian Cancer

November 30th 2021

First-line maintenance treatment with the PARP inhibitor niraparib yielded a clinically meaningful and statistically significant improvement in progression-free survival vs placebo in Chinese patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status, according to data from the phase 3 PRIME trial.

Mirvetuximab Soravtansine Shows Promising Topline Results in FRα-High, Platinum-Resistant Ovarian Cancer

November 30th 2021

The antibody-drug conjugate mirvetuximab soravtansine has shown promising response rates and a favorable toxicity profile in patients with folate receptor alpha-high, platinum-resistant ovarian cancer who have received previous treatment with bevacizumab.

FDA Approves Pafolacianine Sodium Injection for Ovarian Cancer Identification

November 29th 2021

The FDA has approved pafolacianine sodium injection (Cytalux) for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.

Dr. Erickson on PARP Inhibitor Maintenance Therapy in BRCA-Mutated Ovarian Cancer

November 24th 2021

Britt Erickson, MD, discusses the benefit of PARP inhibitor maintenance therapy in patients with BRCA-mutated ovarian cancer.

CTLA-4 Inhibitor AGEN1181 Shows Early Activity in Heavily Pretreated Advanced Solid Tumors

November 23rd 2021

AGEN1181, a next-generation CTLA-4 inhibitor, exhibited clinical activity both as a monotherapy and in combination with balstilimab in heavily pretreated patients with advanced solid tumors.

AK112/Olaparib Combo Under Exploration in BRCA1/2 Wild-Type, Recurrent Ovarian Cancer

November 17th 2021

The combination of the PD-1/VEGF bispecific antibody AK112 and the PARP inhibitor olaparib is under investigation as a potential treatment option for patients with BRCA1/2 germline wild-type, platinum-sensitive, recurrent ovarian cancer as part of a phase 1b/2 trial.

SL-172154 Shows Favorable Tolerability in Platinum-Resistant Ovarian Cancer

November 17th 2021

The investigative agent SL-172154 was found to be well tolerated, with no dose-limiting toxicities observed, in patients with platinum-resistant ovarian cancer, according to findings from a phase 1 dose-escalation trial presented during the 2021 SITC Annual Meeting.

Beyond the Peer-Review Publication: Addressing Implications of Research for Patients

November 4th 2021

Maurie Markman, MD, discusses the need for peer-reviewed publications to encourage further discussion and debate, challenge existing ideas or dogma, or provide support for current biological concepts or in the clinical realm for treatment of patients.

Dr. Memarzadeh on the Potential for Frontline Combinations in Ovarian Cancer

November 2nd 2021

Sanaz Memarzadeh, MD, PhD, discusses the potential for frontline combination therapy regimens in ovarian cancer.

Dr. Salani on Future Research Opportunities in Recurrent Ovarian Cancer

October 29th 2021

Ritu Salani, MD, MBA, discusses future research opportunities for improving the treatment of patients with recurrent ovarian cancer.

Dr. Venkat on Unmet Needs in Ovarian Cancer

October 28th 2021

Puja S. Venkat, MD, discusses unmet needs in ovarian cancer.

Dr. Brown on the Utility of PARP Inhibitors in Recurrent Platinum-Sensitive Ovarian Cancer

October 27th 2021

Jubilee Brown, MD, discusses the utility of PARP inhibitors in patients with recurrent platinum-sensitive ovarian cancer.

Nemvaleukin Alfa Plus Pembrolizumab Gets Fast Track Status for Platinum-Resistant Ovarian Cancer

October 26th 2021

The FDA has granted a fast track designation to the interleukin-2 variant immunotherapy nemvaleukin alfa for use in combination with pembrolizumab in the treatment of patients with platinum-resistant ovarian cancer.

Dr. Secord on the Design of the OReO Trial in Ovarian Cancer

October 19th 2021

Angeles A. Secord, MD, discusses the design of the phase 3b OReO trial in ovarian cancer.

Bicycle Toxin Conjugates Showcase Early Activity and Tolerability in Urothelial, Ovarian Cancers

October 19th 2021

The bicycle toxin conjugates BT5528 and BT8009 have showcased preliminary signs of antitumor activity and encouraging tolerability when administered to patients with solid tumors such as urothelial cancer and ovarian cancer.

Dr. Lai on the Role of Maintenance Therapy and Secondary Cytoreduction in Ovarian Cancer

October 12th 2021

Tiffany S. Lai, MD, discusses the role of maintenance therapy and secondary cytoreduction in ovarian cancer.

Dr. Venkat on Treatment Considerations in Ovarian Cancer

October 11th 2021

Puja S. Venkat, MD, discusses treatment considerations for patients with ovarian cancer.

Dr. Secord on Treatment Considerations in Platinum-Sensitive Ovarian Cancer

October 7th 2021

Angeles A. Secord, MD, discusses the individual therapeutic preferences and treatment considerations for patients with platinum-sensitive ovarian cancer.

Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer

October 7th 2021

Dr. Moore discusses the basis for studying the combination of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer, data that has been generated with the combination from the phase 1/2 FRAME trial, and the potential role for the combination in clinical practice.